Prochlorperazine induces central antinociception mediated by the muscarinic system

Pharmacological Research

Volumn 50, Issue 3, 2004, Pages 351-358

  Ghelardini, Carla ^a   Galeotti, Nicoletta ^a   Uslenghi, Carla ^b   Grazioli, Irene ^b   Bartolini, Alessandro ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Solvay Pharma SpA   (Italy)

Author keywords

Acetylcholine; antisense oligodeoxynucleotide; aODN; degenerate oligodeoxynucleotide; dODN; HC 3; hemicolinium 3 hydrobromide; i.c.v.; i.p.; intracerebroventricular; intraperitoneal; M1 muscarinic receptor subtype; Prochlorperazine; s.c.; subcutaneous

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ACETYLCHOLINE; AMITRIPTYLINE; AMPHETAMINE; ANTISENSE OLIGONUCLEOTIDE; ATROPINE; BACLOFEN; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HEMICHOLINIUM 3; MORPHINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NALOXONE; OPIATE ANTAGONIST; PIRENZEPINE; PROCHLORPERAZINE; QUINPIROLE;

ACETYLCHOLINE RELEASE; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; HOT PLATE TEST; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; TASK PERFORMANCE;

ANALGESICS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MORPHINE; PAIN MEASUREMENT; PROCHLORPERAZINE; QUINPIROLE; RECEPTORS, DOPAMINE D2; RECEPTORS, MUSCARINIC;

EID: 3042691393     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2004.02.005     Document Type: Article

References (36)

1. Hamik A., Peroutka S.J. Differential interactions of traditional and novel antiemetic with dopamine D2 and 5-hydroxytriptamine 3 receptors. Cancer Chemother. Pharmacol. 24:1989;307-310
2. Olver I.N., Wolf M., Laidlaw C., Bishop J.F., Cooper I.A., Matthews J., et al. A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dosemetoclopramide as antiemetics for cancer chemotherapy. Eur. J. Cancer. 8A:1992;1798-1802
3. Crucitt M.A., Hyman W., Grote T., Tester W., Madajewicz S., Yee S., et al. Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. Clin. Ther. 18:1996;778-788
4. Tramèr M.R., Reynold D.J.M., Stoner N.S., Moore R.A., McQuay H.J. Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review. Eur. J. Cancer. 34:1998;1836-1844
5. Patterson K.W., Armstrong C., Timon D., O'Toole D., Keane P.W. Buccal prochlorperazine as an antiemetic for day care surgery. Ir. Med. J. 86:1993;186-188
6. Van den Berg A.A. A comparison of ondansetron and prochlorperazine for prevention of nausea and vomiting after tympanoplasty. Can. J. Anaesth. 43:1996;939-945
7. Williams P.I., Smith M. An assessment of prochlorperazine buccal for prevention of nausea and vomiting during intravenous patient-controlled analgesia with morphine following abdominal hysterectomy. Eur. J. Anaesthesiol. 16:1999;638-645
8. Ordog G.J., Vann P.W., Owashi N.D., Wasserberger J., Herman L.S., Balasubramaniam S. Intravenous prochlorperazine for the rapid control of vomiting in the emergency department. Ann. Emerg. Med. 13:1984;253-258
9. Cunningham D., Bradley C.J., Forrest G.J., Hutcheon A.W., Adams L., Sneddon M., et al. A randomised trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur. J. Cancer Clin. Oncol. 24:1988;685-689
10. Helson L. Total control of chemotherapy induced emesis. Anticancer Res. 12:1992;2243-2244
11. Matsui K., Fukuoka M., Takada M., Kusunoki Y., Yana T., Tamura K., et al. Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Br. J. Cancer. 73:1996;217-221
12. Hesketh P.J., Gandara D.R., Hesket A.M., Edelman M., Webber L.M., MaManus M., et al. Improved control of high-dose cisplatin-induced acute emesis with addition of prochlorperazine to granisetron/dexamethasone. Cancer J. Sci. Am. 3:1997;180-183
13. Raskin NJ. Headache. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, editors. Harrison's principles of internal medicine, 13th ed. New York: McGraw-Hill Inc.; 1994. p. 65-71.
14. Nattero G., Agostoni A., Brandi G., Cottino A., Gai V., Gastaldi L., et al. Therapeutic possibilities in idiopathic headaches. Analysis of about 1000 cases. Miner. Med. 67:1976;1999-2006
15. Thomas S.H., Stone C.K., Ray V.G., Whitely T.W. Intravenous versus rectal prochlorperazine in the treatment of benign vascular or tension headache: a randomized, prospective, double blind trial. Ann. Emerg. Med. 24:1994;923-927
16. Jones J., Pack S., Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Am. J. Emerg. Med. 14:1996;262-264
17. Coppola M., Yealy D.M., Leibold R.A. Randomized placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann. Emerg. Med. 26:1995;541-546
18. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. Chemother. 12:1957;12-15
19. O'Callaghan J.P., Holtzman S. Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure. J. Pharmacol. Exp. Ther. 192:1975;497-505
20. Koster R., Anderson M., De Beer E.J. Acetic acid for analgesic screening. Fed. Proc. 18:1959;412
21. Vaught J., Pelley K., Costa L.G., Sether P., Enna S.J. A comparison of the antinociceptive responses to GABA-receptor agonists THIP and baclofen. Neuropharmacology. 24:1985;211-216
22. Whitesell L., Geselowitz D., Chavany C., Fahmy B., Walbridge S., Alger J., et al. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 90:1993;4665-4669
23. Shapiro R.A., Scherer N.M., Habecke B.A., Subers E.M., Nathanson N.M. Isolation, sequence, and functional expression of the mouse M1 muscarinic acetylcholine receptor gene. J. Biol. Chem. 263:1988;18397-18403
24. Giovannini M.G., Casamenti F., Nistri A., Paoli F., Pepeu G. Effect of thyrotropin releasing hormone (TRH) on acetylcholine release from different brain areas investigated by microdialysis. Br. J. Pharmacol. 102:1991;363-368
25. Paxinos G, Watson G. The rat brain in stereotaxic coordinates. New York: Academic Press; 1982.
26. Damsma G., Lammerts Van Bueren D., Westerink B.H.C., Horn A.S. Determination of acetylcholine in the femtomole range by means of HPLC, a post-column enzyme reactor, and electrochemical detection. Chromatographia. 24:1987;827-831
27. Giovannini M.G., Mutolo D., Bianchi L., Michelassi A., Pepeu G. NMDA receptor antagonists decrease GABA outflow from the septum and increase acethylcholine outflow from the hippocampus: a microdialysis study. J. Neurosci. 44(3):1991;1358-1365
28. Kamei J., Saitoh A. Involvement of dopamine D2 receptor-mediated functions in the modulation of morphine-induced antinociception in diabetic mouse. Neuropharmacology. 35:1996;273-278
29. Schreiber S., Backer M.M., Weizman R., Pick C.G. Augmentation of opioid induced antinociception by the antipsychotic drug risperidone in mice. Neurosci. Lett. 228(1):1997;25-28
30. 2 antagonist response? Eur. J. Pharmacol. 128:1986;93-98
31. 2 dopamine receptors and modulation of spontaneous acetylcholine (ACh) release from rat striatal synaptosomes. Br. J. Pharmacol. 122:1997;286-290
32. 2 dopamine receptor activation inhibits basal and forskolin-evoked acetylcholine release from dissociated striatal cholinergic interneurones. Brain Res. 749:1997;147-151
33. Bartolini A., Ghelardini C., Fantetti L., Malcangio M., Malmberg-Aiello P., Giotti A. Role of muscarinic receptor subtypes in central antinociception. Br. J. Pharmacol. 105:1992;77-82
34. Iwamoto E.T., Marion L. Characterization of the antinociception produced by intrathecally administered muscarinic agonists in rats. J. Pharmacol. Exp. Ther. 266:1993;329-338
35. 1 receptors. Br. J. Pharmacol. 129:2000;1633-1640
36. Bartolini A., Galli A., Ghelardini C., Giotti A., Malcangio M., Malmberg-Aiello P., et al. Antinociception induced by systemic administration of local anaesthetics depends on a cholinergic mechanism. Br. J. Pharmacol. 92:1987;711-721